Scope
The IAP chapter describes recognition and initial treatment of paracetamol poisoning in children. Its main usable decision points are prompt stabilization, correct selection of patients for the Rumack–Matthew nomogram, timely N-acetylcysteine and monitoring for hepatic injury. This is deliberately a focused summary: the source contains an unresolved instruction in its acetylcysteine stopping flowchart and inconsistent presentation of infusion regimens, so a complete dosing or cessation protocol cannot be established from it.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Identify severe toxicity
- Urgent warning features include altered mental status, hypoglycaemia, persistent vomiting, jaundice and right-upper-quadrant tenderness. The chapter also flags INR >2, arterial pH <7.3 and clinical acute liver failure. [1]
- Consider paracetamol toxicity in a child with otherwise unexplained acute liver failure. [1]
Use the nomogram only for its intended exposure
- The Rumack–Matthew nomogram applies to a single acute ingestion of immediate-release paracetamol, using serum concentration against time from ingestion beginning at 4 hours. [1]
- Do not apply this nomogram to repeated or staggered ingestion or uncertain ingestion time. The chapter states that it is unreliable for sustained-release preparations. [1]
- At 4 hours, the chapter’s treatment threshold is serum paracetamol ≥150 µg/mL for starting NAC. This is a time-specific nomogram value, not a threshold to apply unchanged to a later sample. [1]
Stabilize and consider early decontamination
- Assess airway, breathing and circulation; monitor vital signs, glucose and neurological state. Correct hypoglycaemia, acidosis and electrolyte abnormalities, and manage coagulopathy when clinically indicated. [1]
- Activated charcoal is described within 2 hours of ingestion, with an extended window for sustained-release preparations. The stated dose is 1 g/kg, up to 50 g; do not give it with an unprotected airway. [1]
Start NAC when indicated without avoidable delay
- Start NAC for a concentration above the treatment line, presentation more than 8 hours after a toxic dose, or unknown ingestion time with raised transaminases. [1]
- The chapter recommends empiric NAC if the history is unreliable or clinical toxicity is suspected. Do not delay NAC for a clearly toxic ingestion or withhold it because laboratory results will be delayed. [1]
Monitor liver injury and escalate care
- At 18–20 hours, reassess serum paracetamol, ALT and INR. The narrative lists rising ALT, abnormal INR, detectable paracetamol or clinical instability as reasons to continue NAC; it does not supply a reliable complete stopping rule. [1]
- Assess hepatic injury and synthetic function with transaminases and PT/INR, renal involvement with urea and creatinine, and glucose and acid–base status. The chapter also includes serum ammonia in assessment of encephalopathy. [1]
- The disposition table places symptomatic or uncertain ingestions in hospital care and severe hepatic injury, coagulopathy or encephalopathy in a paediatric intensive-care assessment pathway. It refers to King’s College criteria for transplant referral without supplying the criteria. [1]
Limitations and use
- The source flowchart contains the unresolved instruction “Please verify text here” for stopping acetylcysteine. Its narrative describes a 3-infusion 21-hour regimen, while the flowchart refers to a second-bag 16-hour regimen. This summary therefore does not provide a complete NAC infusion or stopping protocol.
- The nomogram is restricted to a single, known-time, immediate-release ingestion. The source does not provide a complete alternative algorithm for staggered, repeated, sustained-release or unknown-time exposure.
- King’s College criteria are mentioned but not given; no transplant thresholds are inferred. The listed laboratory abnormalities do not form a complete admission or discharge rule.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Paracetamol (Acetaminophen) Poisoning in Children
Selected recommendation material consulted
Publication details
- Issuing organisation
- IAP
- Resource type
- Practice guideline · House clinical summary
- Source setting
- India
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.